ArticleCell reports2021
Neurotoxins subvert the allosteric activation mechanism of SARM1 to induce neuronal loss.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Direct activation of SARM1 by dsDNA is not supported by biochemical and cellular evidence.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Review
- Quantification of SARM1 NADase Activity in Human Peripheral Blood Mononuclear Cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- SARM1 activation promotes axonal degeneration via a two-step phase transition.Nature chemical biology · 2026Article
- Programmed axon degeneration: mechanism, inhibition and therapeutic potential.Nature reviews. Neuroscience · 2026Review
- A metabolic cell death program downstream of SARM1 couples NADProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Therapeutic safety implications of SARM1 active site inhibitors: subinhibitory concentrations cause neurodegeneration.npj drug discovery · 2025Article
- Stepwise activation of SARM1 for cell death and axon degeneration revealed by a biosynthetic NMN mimic.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Programmed neurite degeneration in human central nervous system neurons driven by changes in NADCell death & disease · 2025Article
- Augustus Waller's foresight realized: SARM1 in peripheral neuropathies.Current opinion in neurobiology · 2024Review
- SARM1-Dependent Axon Degeneration: Nucleotide Signaling, Neurodegenerative Disorders, Toxicity, and Therapeutic Opportunities.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2024Review
- Programmed axon death: a promising target for treating retinal and optic nerve disorders.Eye (London, England) · 2024Review
- Thiophenyl Derivatives of Nicotinamide Are Metabolized by the NAD Salvage Pathway into Unnatural NAD Derivatives That Inhibit IMPDH and Are Toxic to Peripheral Nerve Cancers.ACS chemical biology · 2024Article
- Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death.Journal of medicinal chemistry · 2024Review
- Adaptation of a Commercial NADMolecules (Basel, Switzerland) · 2024Article
- SARM1 detection in myelinating glia:Frontiers in cellular neuroscience · 2023Article
- A duplex structure of SARM1 octamers stabilized by a new inhibitor.Cellular and molecular life sciences : CMLS · 2022Article
- Selective inhibitors of SARM1 targeting an allosteric cysteine in the autoregulatory ARM domain.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Structural basis of SARM1 activation, substrate recognition, and inhibition by small molecules.Molecular cell · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Tong WuDepartment of Genetics, Washington University Medical School, St. Louis, MO 63110, USA; Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO 63130, USA.
Jian ZhuDepartment of Genetics, Washington University Medical School, St. Louis, MO 63110, USA; Needleman Center for Neurometabolism and Axonal Therapeutics, Washington University School of Medicine in Saint Louis, St. Louis, MO 63114, USA.
Amy StricklandDepartment of Genetics, Washington University Medical School, St. Louis, MO 63110, USA.
Kwang Woo KoDepartment of Developmental Biology, Washington University Medical School, St. Louis, MO 63110, USA.
Yo SasakiDepartment of Genetics, Washington University Medical School, St. Louis, MO 63110, USA.
Caitlin B DingwallDepartment of Genetics, Washington University Medical School, St. Louis, MO 63110, USA.
Yurie YamadaDepartment of Genetics, Washington University Medical School, St. Louis, MO 63110, USA.
Matthew D FigleyDepartment of Developmental Biology, Washington University Medical School, St. Louis, MO 63110, USA.
Xianrong MaoDepartment of Genetics, Washington University Medical School, St. Louis, MO 63110, USA.
Alicia NeinerDepartment of Genetics, Washington University Medical School, St. Louis, MO 63110, USA.
A Joseph BloomDepartment of Genetics, Washington University Medical School, St. Louis, MO 63110, USA; Needleman Center for Neurometabolism and Axonal Therapeutics, Washington University School of Medicine in Saint Louis, St. Louis, MO 63114, USA.
Aaron DiAntonioDepartment of Developmental Biology, Washington University Medical School, St. Louis, MO 63110, USA; Needleman Center for Neurometabolism and Axonal Therapeutics, Washington University School of Medicine in Saint Louis, St. Louis, MO 63114, USA. Electronic address: diantonio@wustl.edu.
Jeffrey MilbrandtDepartment of Genetics, Washington University Medical School, St. Louis, MO 63110, USA; Needleman Center for Neurometabolism and Axonal Therapeutics, Washington University School of Medicine in Saint Louis, St. Louis, MO 63114, USA. Electronic address: jmilbrandt@wustl.edu.
Washington University in St. Louis · US
Funding
DISSECTION OF SARM1-INDUCED AXON DEGENERATION AND CELL DEATHR01NS087632 · NINDS · WASHINGTON UNIVERSITY · PI Aaron Diantonio, JEFFREY D MILBRANDT · 2014 to 2026
$6.4MRegulating NAD Metabolism to Inhibit Axon Degeneration in Neurodegenerative DiseasesRF1AG013730 · NIA · WASHINGTON UNIVERSITY · PI MILBRANDT, JEFFREY D · 2017 to 2017
$2.8M(PQ#9) Promoting Axon Stability to Prevent Therapy-induced Peripheral NeuropathyR01CA219866 · NCI · WASHINGTON UNIVERSITY · PI DIANTONIO, AARON, MILBRANDT, JEFFREY D · 2017 to 2021
$2.3MNCI NIH HHS R01 CA219866NIA NIH HHS RF1 AG013730NINDS NIH HHS R01 NS087632
Abstract
SARM1 is an inducible TIR-domain NAD
Indexed as
Nerve DegenerationActivation, MetabolicAllosteric RegulationAnimalsArmadillo Domain ProteinsAxonsCatalytic DomainCell DeathCytokinesCytoskeletal ProteinsEnzyme ActivationFemaleGanglia, SpinalHEK293 CellsHumansMale3-acetylpyridineArmadillo Domain ProteinsCytokinesCytoskeletal ProteinsNeurotoxinsNicotinamide-Nucleotide AdenylyltransferaseNicotinamide Phosphoribosyltransferasenicotinamide phosphoribosyltransferase, mouseNmnat1 protein, mousePyridinesSARM1 protein, mousebase exchange reactionmass spectrometrymetabolismmyelinNAMPTneurolytic blockNMNATsciatic nervetibial nerveVacor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.